TSHR and thyroid cancer: A recent study by another group demonstrated increased targeted delivery of doxorubicin, mediated by silicon dioxide nanoparticles (NPs) conjugated with thyroid stimulating-hormone receptor-targeting ligand resulting in a reduction in tumor size and off-target effects in a thyroid cancer in vivo model [71].